欧洲肺癌筛查市场预测至 2030 年 – 区域分析 – 按癌症类型 [非小细胞肺癌 (NSCLC) 和小细胞肺癌]、技术 [低剂量计算机断层扫描 (LDCT)、胸部 X-射线、液体活检等]、年龄组(50 岁及以上和 50 岁以下)和最终用户(医院、诊断中心等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 131    |    Report Code: BMIRE00029047    |    Category: Life Sciences

Europe Lung Cancer Screening Market

欧洲肺癌筛查市场预计将从2022年的5.9325亿美元增长到2030年的10.9099亿美元。预计2022年至2030年复合年增长率为7.9%。

肺癌发病率上升推动欧洲肺癌筛查市场。

<肺癌是全世界死亡的主要原因之一。肺癌筛查是癌症预防方法的重要组成部分。肺癌患者早期诊断预后较好,因此肺癌高危人群应定期进行检查,以发现肺部癌变的形成情况。

根据癌症杂志《肿瘤学年鉴》进行的研究,预计 2023 年欧盟地区将有约 1,261,990 名癌症患者死亡。肺癌死亡率将增加 1% 以上,达到每 10 万人 13.6 人。由于越来越多的英国女性比欧盟女性更早开始吸烟,英国女性肺癌死亡率将下降 13.8%,尽管每 10 万人中 16.2 人的死亡率仍高于欧盟女性。在英国,目前肺癌的死亡率高于乳腺癌,乳腺癌的死亡率为每 10 万 13.5 例。

当研究人员特别检查了另外五个欧盟国家的肺癌死亡率时在英国,他们发现,虽然人口最多的六个国家(法国、德国、意大利、波兰和西班牙)的男性死亡率预计会下降,但法国、意大利和西班牙的女性死亡率将增加约 14% 、 5.6% 和 5% 。研究人员发现,在不同年龄段的女性中,25岁至64岁之间的肺癌预期死亡率有所下降,但65岁至75岁以上的女性中肺癌预期死亡率有所上升,导致总体上升。此外,根据国家生物技术信息中心 (NCBI) 的数据,意大利每年约有 41,000 例新诊断肺癌和 34,000 例死亡。因此,全球肺癌发病率的上升推动了肺癌筛查计划的启动,这反过来又推动了市场的增长。

欧洲肺癌癌症筛查市场概览

欧洲肺癌筛查市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。该地区的增长归因于多种因素,例如肺癌发病率的增加以及人们对侧肺癌筛查和诊断的认识。此外,政府对筛查的支持力度不断加大,也带动了市场的进一步增长。

肺癌患病率的不断上升,使得筛查对于早期发现变得极其重要。建议长期吸烟且没有任何肺癌相关症状的老年人进行肺癌筛查。医生使用低剂量计算机断层扫描 (LDCT) 扫描或 X 射线进行筛查。

根据一篇题为“德国的肺癌”的文章, 2022 年 6 月发表在《胸腔肿瘤学杂志》上的研究显示,癌症是德国第二大常见死亡原因之一,占所有死亡的 25%。在男性中,肺癌位列第二位,仅次于心血管疾病,占全因死亡率的 6.5%。肺癌的年龄标化发病率男性和女性分别为52.1和32.7(每10万人),在男性中位居第二,在女性中位居第三(分别占所有新诊断癌症的13.3%和9.4%)。癌症诊断的平均年龄为70岁(男性)和69岁(女性); 52% 的患者处于 IV 期。由于吸烟习惯的长期变化,自 20 世纪 90 年代以来,女性和男性的发病率趋同。目前,德国有四分之一的男性 (27.0%) 和五分之一的女性 (20.8%) 经常吸烟

到 2030 年欧洲肺癌筛查市场收入及预测(美国)百万美元)

欧洲肺癌筛查市场细分

欧洲肺癌筛查市场细分为癌症类型、技术、年龄组、最终用户和国家。

根据癌症类型,欧洲肺癌筛查市场分为非小细胞肺癌 (NSCLC) 和小细胞肺癌。 2022年,非小细胞肺癌(NSCLC)细分市场在欧洲肺癌筛查市场中占据更大份额。

以技术为基础,欧洲肺癌筛查市场分为胸部 X 光检查、低剂量计算机断层扫描 (LDCT)、液体活检等。 2022年,低剂量计算机断层扫描(LDCT)细分市场在欧洲肺癌筛查市场中占据最大份额。

根据年龄组,欧洲肺癌筛查市场细分为;50 岁及以上和 50 岁以下。2022 年,50 岁及以上人群在欧洲肺癌筛查市场中占据较大份额。

根据最终用户,欧洲肺癌筛查市场筛查市场分为医院、诊断中心等。 2022年,医院细分市场在欧洲肺癌筛查市场中占据最大份额。

按国家划分,欧洲肺癌筛查市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。德国在 2022 年主导欧洲肺癌筛查市场。

Siemens AG、Koninklijke Philips NV、Canon Inc、Medtronic、GE HealthCare、Nuance Communications Inc、和 Intelerad Medical Systems 是欧洲肺癌筛查市场上的一些领先公司。



Europe Lung Cancer Screening Strategic Insights

Strategic insights for Europe Lung Cancer Screening involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-lung-cancer-screening-market-strategic-framework.webp
Get more information on this report

Europe Lung Cancer Screening Report Scope

Report Attribute Details
Market size in 2022 US$ 593.25 Million
Market Size by 2030 US$ 1,090.99 Million
Global CAGR (2022 - 2030) 7.9%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 癌症类型
  • 非小细胞肺癌
  • 小细胞肺癌
By 技术
  • 低剂量计算机断层扫描
  • 胸部X光
  • 液体活检
By 年龄组
  • 50 岁以上和 50 岁以下
By 最终用户
  • 医院
  • 诊断中心
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Nuance Communications Inc
  • GE HealthCare Technologies Inc
  • Medtronic Plc
  • Canon Medical Systems Corp
  • Koninklijke Philips NV
  • Siemens AG
  • Get more information on this report

    Europe Lung Cancer Screening Regional Insights

    The regional scope of Europe Lung Cancer Screening refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-lung-cancer-screening-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Lung Cancer Screening Market

    1. Nuance Communications Inc
    2. GE HealthCare Technologies Inc
    3. Medtronic Plc
    4. Canon Medical Systems Corp
    5. Koninklijke Philips NV
    6. Siemens AG
    Frequently Asked Questions
    How big is the Europe Lung Cancer Screening Market?

    The Europe Lung Cancer Screening Market is valued at US$ 593.25 Million in 2022, it is projected to reach US$ 1,090.99 Million by 2030.

    What is the CAGR for Europe Lung Cancer Screening Market by (2022 - 2030)?

    As per our report Europe Lung Cancer Screening Market, the market size is valued at US$ 593.25 Million in 2022, projecting it to reach US$ 1,090.99 Million by 2030. This translates to a CAGR of approximately 7.9% during the forecast period.

    What segments are covered in this report?

    The Europe Lung Cancer Screening Market report typically cover these key segments-

  • 癌症类型 (非小细胞肺癌, 小细胞肺癌)
  • 技术 (低剂量计算机断层扫描, 胸部X光, 液体活检)
  • 年龄组 (50 岁以上和 50 岁以下)
  • What is the historic period, base year, and forecast period taken for Europe Lung Cancer Screening Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Lung Cancer Screening Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in Europe Lung Cancer Screening Market?

    The Europe Lung Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Nuance Communications Inc
  • GE HealthCare Technologies Inc
  • Medtronic Plc
  • Canon Medical Systems Corp
  • Koninklijke Philips NV
  • Siemens AG
  • Who should buy this report?

    The Europe Lung Cancer Screening Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Lung Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.